1. Home
  2. USIO vs SCYX Comparison

USIO vs SCYX Comparison

Compare USIO & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Usio Inc.

USIO

Usio Inc.

N/A

Current Price

$2.77

Market Cap

58.8M

Sector

Finance

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

N/A

Current Price

$5.10

Market Cap

51.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
USIO
SCYX
Founded
1998
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.8M
51.1M
IPO Year
1999
2014

Fundamental Metrics

Financial Performance
Metric
USIO
SCYX
Price
$2.77
$5.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.00
$3.00
AVG Volume (30 Days)
406.2K
240.3K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
0.01
N/A
Revenue
$28,200,535.00
$257,000.00
Revenue This Year
$12.15
N/A
Revenue Next Year
$8.57
$608.78
P/E Ratio
$267.00
N/A
Revenue Growth
12.69
N/A
52 Week Low
$1.03
$0.57
52 Week High
$2.98
$5.62

Technical Indicators

Market Signals
Indicator
USIO
SCYX
Relative Strength Index (RSI) 68.80 61.14
Support Level $1.28 $4.65
Resistance Level $2.98 $5.58
Average True Range (ATR) 0.23 0.35
MACD 0.04 -0.01
Stochastic Oscillator 85.80 59.55

Price Performance

Historical Comparison
USIO
SCYX

About USIO Usio Inc.

Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: